Transforming growth factor beta receptor type II dominant negative variant (TGFBR2 (dominant negative))

The **Transforming growth factor beta receptor type II dominant negative variant** is a genetically engineered form of the TGF-beta type II receptor (TGFBR2), which normally functions as a transmembrane serine/threonine kinase and is an essential mediator of TGF-beta signaling. The wild-type receptor binds TGF-beta ligand, recruiting and phosphorylating the type I receptor (TGFBR1), which in turn phosphorylates intracellular SMAD2/3 proteins to regulate gene expression controlling cell proliferation, differentiation, apoptosis, and immune responses[1][2][3][6][8]. The **dominant negative variant** typically consists of a mutant TGFBR2 receptor that retains the ability to bind ligand but lacks functional kinase activity. When overexpressed in cells, it dimerizes with wild-type receptors and impairs normal signal transduction by blocking phosphorylation of downstream targets. This variant is a widely used research tool to block TGF-beta signaling in vitro and in vivo and is investigated in gene therapy strategies to inhibit pathological TGF-beta activity, as in cancer or fibrosis models[2][8]. Note: The phrase "dominant negative" does not refer to a naturally occurring genetic variant, but to a specific artificial mutation or truncation—precise details (such as which amino acid change is introduced) may vary between constructs described in the literature. It is not an approved drug or standard therapeutic target in itself but rather considered a research tool or gene therapy candidate. The wild-type TGFBR2 is a validated therapeutic target in oncology, fibrosis, and diseases involving excessive or dysregulated TGF-beta signaling[1][5][8].

Other names

TGF-beta type II receptor (dominant negative)DN TGF-betaRIITGFBR2-DNTGF-βRII dominant negative

Dominant negative TGFBR2 acts by inhibiting the function of wild-type TGFBR2, thereby blocking TGF-beta-induced signaling and downstream SMAD phosphorylation[2][4][6][8]. Drugs targeting this pathway are typically: Ligand (TGF-beta) neutralization, Small molecule inhibition of downstream kinases, Monoclonal antibodies or ligand traps, Gene therapy approaches to deliver dominant negative variants.